Clinical Trial Update: Clinical and Biological Effects of Anti-IgE (Omalizumab) in Patients With Bilateral Nasal Polyposis and Asthma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the clinical and biological effects of omalizumab in patients with bilateral nasal polyposis and asthma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Nasal Polyposis

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: University Hospital, Ghent | Conditions: Nasal Polyposis, Asthma | Phase 2 | Status: COMPLETED